Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses
{{output}}
Chronic hepatitis C (CHC) is a risk factor for hepatic osteodystrophy, increasing osteoporosis and fracture risks. While historical pegylated interferon/ribavirin (PEG-IFN/RBV) showed variable bone effects, the newer direct-acting antivirals' (DAAs) impact is... ...
